関連する実験動画
Updated: Jun 19, 2025

04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
342
肥満の転換:多受容体薬の進歩
Christine M Kusminski1, Diego Perez-Tilve2, Timo D Müller3
1Touchstone Diabetes Center, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Cell
|July 26, 2024
まとめ
グルカゴン型ペプチド-1 (GLP-1) 受容体を標的とする新しい腸ホルモンポリアゴニストは,体重を30%まで大幅に減らすことができます. これらの高度な抗肥満薬は 手術の代替薬として有望です
科学分野:
- 薬理学について
- 内分泌学
- 代謝 疾患
背景:
- 医者は長い間,過剰な体脂肪を減らすために薬学的方法を模索してきました.
- 最近の生物化学工学の進歩により 肥満管理のための新しい治療薬が開発されました
研究 の 目的:
- 体重減少のためのGLP-1ベースのポリアゴニストの開発と有効性を検討する.
- これらの新しい抗肥満薬の 多様性を強調する
主な方法:
- GLP-1受容体アゴニストとポリアゴニストに関する最近の科学文献のレビュー.
- 体重減少と関連する健康上の利点の基礎となる薬理学的メカニズムの分析.
主要な成果:
- GLP-1ベースのポリアゴニストは,グルカゴンおよび/またはGIP受容体を組み込み,体重を大幅に減らす (最大20%〜30%).
- これらの薬剤は,血糖値,脂肪肝,腎臓疾患,心臓血管の健康,脂肪組織に好ましい効果を示しています.
結論:
- 腸内ホルモンのポリアゴニストは 抗肥満の薬剤療法における 重要な突破口です
- これらの新しい介入は 肥満と関連疾患の管理に 肥満外科手術の薬学的な代替手段として 期待されています
関連する概念動画
Glucagon-like Receptor Agonists
312
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
312
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Antidepressant Drugs: MAOIs and Other Agents
209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
G Protein-coupled Receptors
11.6K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
11.6K
Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K

